SEC Form 4 · accession 0001203311-17-000072
SEATTLE GENETICS INC /WA · SGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eric Dobmeier
Officer — Chief Operating Officer
Period of report
Aug 31, 2017
Accepted (ET)
Sep 5, 2017 · 7:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001060736
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 31, 2017 | M | 25,000 | $15.46 | A | 142,424 | D | |
| Common StockF2,F1 | Aug 31, 2017 | S | 25,000 | $52.2357 | D | 117,424 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F3 | $15.46 | Aug 31, 2017 | M | 25,000 | D | — | Aug 24, 2021 | Common Stock | 25,000 | 18,089 | D |
Explanation of responses
- F1Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
- F2Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $52.00 to $52.68. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F3Shares vested at a rate of 25% on 8/24/12 and monthly thereafter until all the shares were fully vested on 8/24/15.